What does JUPITER stand for?

Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin. The acronym was chosen to reflect the trial's goal of justifying statin use in a population that did not meet traditional LDL-based prescribing criteria.

What is hsCRP and why does it matter?

High-sensitivity C-reactive protein is a blood test that measures systemic inflammation. Levels above 2.0 mg/L are associated with increased cardiovascular risk even when cholesterol is normal. JUPITER showed that treating this inflammation-driven risk with a statin reduced heart attacks and strokes by 44%.

Was rosuvastatin the only statin that could have worked?

JUPITER tested only rosuvastatin 20 mg. No head-to-head trial has tested whether other statins would produce the same result in this specific hsCRP-elevated, low-LDL population. The benefit likely comes from the class effect of potent LDL reduction plus anti-inflammatory properties common to all statins, but this is an inference, not a proven fact.

Why was the JUPITER trial stopped early?

The Data Safety Monitoring Board halted the trial at a median of 1.9 years (planned duration was 4 years) because the cardiovascular benefit in the rosuvastatin arm crossed pre-specified efficacy boundaries. Continuing to give half the participants a placebo was deemed unethical once the benefit was clear.

Does rosuvastatin cause diabetes?

In JUPITER, physician-reported diabetes was more common in the rosuvastatin group (3.0% vs 2.4%, p = 0.01). This risk has been confirmed in subsequent meta-analyses. Current FDA labeling for rosuvastatin includes a warning about increased blood glucose and HbA1c. For most patients, the cardiovascular benefit outweighs this risk, but individuals near the pre-diabetic threshold should be monitored.

Should I ask my doctor to check my hsCRP?

If your 10-year cardiovascular risk is in the borderline or intermediate range (5-20% by the pooled cohort equation) and you are not already on a statin, an hsCRP test can provide useful information. The 2018 ACC/AHA guidelines list hsCRP ≥ 2.0 mg/L as a risk-enhancing factor that may support starting statin therapy. If you are already clearly high-risk or clearly low-risk, the test is less likely to change management.

What was the number needed to treat in JUPITER?

Over the 1.9-year median follow-up, approximately 95 patients needed to be treated with rosuvastatin for one year to prevent one primary cardiovascular event. Projected over five years, the NNT drops to roughly 25, which is comparable to secondary prevention statin trials.

How did JUPITER influence current cholesterol guidelines?

The 2013 and 2018 ACC/AHA cholesterol guidelines recognized hsCRP ≥ 2.0 mg/L as a risk-enhancing factor for borderline-risk patients. JUPITER did not lead to universal CRP screening, but it expanded the definition of who might benefit from statin therapy beyond traditional LDL-centric criteria.

Did JUPITER prove that inflammation causes heart disease?

JUPITER showed that treating a population selected by inflammatory markers reduced cardiovascular events. It could not definitively separate the LDL-lowering effect from the anti-inflammatory effect of rosuvastatin. The 2017 CANTOS trial, which used a pure anti-inflammatory drug with no effect on LDL, provided stronger evidence that inflammation is a causal pathway in atherosclerosis.

Is generic rosuvastatin as effective as brand-name Crestor?

Yes. The FDA requires generic drugs to demonstrate bioequivalence to the brand-name product. Generic rosuvastatin 20 mg delivers the same active ingredient at the same dose. The patent on Crestor expired in 2016, and generic versions are now widely available at substantially lower cost.

JUPITER Trial: A Plain-English Overview of What It Established

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for JUPITER Trial: A Plain-English Overview of What It Established Image: HealthRX.com clinical image

At a glance

| Field | Detail | |---|---| | Full title | Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) | | N | 17,802 | | Intervention | Rosuvastatin 20 mg daily | | Comparator | Matching placebo | | Population | Men ≥ 50 and women ≥ 60 with LDL-C <130 mg/dL and hsCRP ≥ 2.0 mg/L | | Duration | Median 1.9 years (stopped early by the Data Safety Monitoring Board) | | Primary endpoint | First major cardiovascular event (nonfatal MI, nonfatal stroke, arterial revascularization, hospitalization for unstable angina, or confirmed CV death) | | Key result | HR 0.56 (95% CI 0.46-0.69), p < 0.00001 | | Published | NEJM, November 2008 |

The Question JUPITER Asked

Before 2008, statins were prescribed almost exclusively based on LDL cholesterol levels. If your LDL was below 130 mg/dL and you had no diabetes or known heart disease, guidelines said you probably did not need a statin. But cardiologists had noticed something uncomfortable: roughly half of all heart attacks happen in people whose LDL cholesterol is not elevated.

High-sensitivity C-reactive protein (hsCRP), a blood marker of systemic inflammation, had been linked to cardiovascular risk in observational studies for years. The question was whether treating people who had high inflammation but "normal" cholesterol would actually prevent heart attacks and strokes, or whether hsCRP was just a bystander marker.

JUPITER was designed to answer that question with a hard-endpoint, placebo-controlled trial.

Who Got In (and Who Didn't)

The enrollment criteria were specific. Participants had to be apparently healthy, with no history of heart disease, stroke, or diabetes. Men had to be at least 50, women at least 60. The two laboratory gates were an LDL-C below 130 mg/dL (median at entry was 108 mg/dL) and an hsCRP of 2.0 mg/L or higher (median at entry was 4.2 mg/L).

Exclusions filtered out people already taking statins or other lipid-lowering drugs, anyone on hormone replacement therapy, and those with triglycerides above 500 mg/dL, inflammatory conditions like lupus or rheumatoid arthritis, or uncontrolled hypertension. The trial enrolled participants across 26 countries and 1,315 sites between February 2003 and December 2006, according to the primary publication.

The resulting population was ethnically diverse: about 71% white, 13% Hispanic, 12% Black, and 4% other backgrounds. About 38% of participants were women, a higher proportion than many earlier statin trials.

What They Were Given

Randomization assigned 8,901 participants to rosuvastatin 20 mg once daily and 8,901 to placebo. The dose was not titrated. There was no run-in period to weed out non-compliers, which makes the results more applicable to real clinical practice.

Rosuvastatin (brand name Crestor) is the most potent statin on a per-milligram basis. At 20 mg, it typically lowers LDL-C by about 50%. In JUPITER, the median LDL in the rosuvastatin arm fell from 108 mg/dL to 55 mg/dL. The median hsCRP dropped by 37%, from 4.2 to 2.2 mg/L.

The HealthRX.com Dual-Target Framework: Why Both Numbers Mattered

One detail that sets JUPITER apart from other statin trials is the opportunity to separate two effects: LDL lowering and inflammation lowering. The investigators ran pre-specified subgroup analyses asking whether the benefit tracked more closely with one biomarker or the other.

The answer was both. Participants who achieved both an LDL <70 mg/dL and an hsCRP <2 mg/L had the largest risk reduction (HR 0.35). Those who hit only one target still benefited, but less. This dual-biomarker signal became the basis for what some cardiologists now call "residual inflammatory risk," a concept that did not exist in guidelines before JUPITER published.

| Achieved target | HR for primary endpoint | |---|---| | LDL <70 and hsCRP <2 | 0.35 | | LDL <70 only | 0.55 | | hsCRP <2 only | 0.62 | | Neither target | Reference |

This framework suggests that checking hsCRP after starting a statin gives you information you cannot get from the lipid panel alone. It is not a universally adopted practice yet, but the data supporting it originates here.

Primary and Secondary Results

The trial was stopped 1.9 years into a planned 4-year follow-up. The Data Safety Monitoring Board determined that the benefit was overwhelming and it would be unethical to continue giving half the participants a placebo.

Primary endpoint breakdown

| Component | Rosuvastatin (n=8,901) | Placebo (n=8,901) | HR (95% CI) | |---|---|---|---| | Any primary event | 142 (0.77/100 py) | 251 (1.36/100 py) | 0.56 (0.46-0.69) | | Nonfatal MI | 22 | 62 | 0.35 (0.22-0.58) | | Nonfatal stroke | 30 | 58 | 0.52 (0.33-0.80) | | Revascularization | 71 | 131 | 0.54 (0.41-0.72) | | Unstable angina hospitalization | 16 | 27 | 0.59 (0.32-1.10) | | CV death | 12 | 22 | 0.55 (0.27-1.10) |

The primary publication also reported a 20% reduction in all-cause mortality (HR 0.80, 95% CI 0.67-0.97, p = 0.02), though the trial was not powered for this endpoint. The finding was consistent but should be interpreted cautiously given the early stop.

Venous thromboembolism, a pre-specified secondary endpoint, was reduced by 43% (HR 0.57, 95% CI 0.37-0.86). This was an unexpected finding that prompted separate follow-up research into anti-thrombotic properties of statins.

Number needed to treat

Over the median 1.9-year follow-up, the NNT was 95 to prevent one primary event per year of treatment. Projected over five years using the observed event curves, the NNT drops to roughly 25, comparable to statin NNTs in higher-risk secondary prevention populations.

Safety and Side Effects

Muscle-related complaints (myalgia, weakness) occurred in 16.0% of the rosuvastatin group versus 15.4% of the placebo group, a difference that was not statistically significant. No cases of rhabdomyolysis were reported in either arm.

Two safety signals did emerge. The rosuvastatin group had a higher physician-reported incidence of new diabetes diagnoses: 270 versus 216 cases (p = 0.01). This works out to about 1 extra diabetes case per 167 patients treated over 1.9 years. The association between high-potency statins and incident diabetes has been confirmed in subsequent meta-analyses and is now listed on the rosuvastatin prescribing label.

HbA1c levels were also slightly higher in the rosuvastatin arm (5.9% vs 5.8% median). For patients already near the pre-diabetic threshold, this is clinically relevant.

Hepatic transaminase elevations > 3x ULN occurred at similar rates in both groups. Renal adverse events were not significantly different.

The Criticisms That Stuck

JUPITER drew more scrutiny than most cardiovascular trials. Several criticisms remain relevant today.

Early stopping bias. Trials stopped early for benefit tend to overestimate treatment effects. A 2010 analysis in JAMA estimated that early-stopped trials overstate relative risk reductions by an average of 29%. The true HR might be closer to 0.65-0.70 than 0.56. The trial's independent DSMB followed pre-specified stopping rules, but the short follow-up (median 1.9 years) limits confidence in long-term safety and durability.

Industry sponsorship. AstraZeneca funded the trial, and the company held the patent on rosuvastatin during the study period. The lead investigator, Paul Ridker, was also a co-inventor on patents related to hsCRP testing. These financial relationships were disclosed in the publication but have been cited in editorials questioning whether hsCRP testing was promoted partly for commercial reasons.

Absolute risk was low. The placebo group's annual event rate was only 1.36 per 100 person-years. Critics argued that medicating a large population at low absolute risk means many people take a daily pill (with side effects) so that a small number benefit. The 2013 ACC/AHA cholesterol guidelines ultimately chose not to make hsCRP a primary screening tool, though they acknowledged it could inform borderline decisions.

Generalizability. The trial excluded people with diabetes, those already on statins, and anyone with known cardiovascular disease. It tested only one statin at one dose. Whether the same results would apply to other statins, or to populations with different baseline risk profiles, remains an extrapolation.

What Changed in Clinical Practice

JUPITER did not lead to universal hsCRP screening. That was one of its more controversial proposals, and most guideline committees stopped short of endorsing it. What the trial did change, in measurable ways:

The 2013 ACC/AHA guidelines listed hsCRP ≥ 2.0 mg/L as a "risk-enhancing factor" that could tip the decision toward statin therapy when the 10-year ASCVD risk is borderline (5-7.5%). This was a direct acknowledgment of JUPITER's population and findings.

The trial also shifted the conversation about who is "low risk." Before JUPITER, a person with an LDL of 108 and no diabetes would almost never receive a statin prescription. After JUPITER, if that person also had an hsCRP of 4.0, the discussion changed.

The subsequent CANTOS trial (2017) tested a pure anti-inflammatory drug, canakinumab, and confirmed that reducing inflammation without lowering LDL does reduce cardiovascular events. This validated JUPITER's hypothesis that inflammation is a causal pathway, not just a marker.

Where We Stand Now

Rosuvastatin is available as a generic. The cost barrier that existed during the JUPITER era (when Crestor cost over $200/month) is largely gone. A 90-day supply of generic rosuvastatin 20 mg typically costs under $15 in the United States.

The debate about routine hsCRP testing continues. Some clinicians check it in every patient with intermediate cardiovascular risk. Others view it as unnecessary if the patient already qualifies for a statin based on their 10-year ASCVD risk score. Both positions can cite guideline language in their favor.

For patients who have already had a cardiovascular event, the question has moved past JUPITER entirely. The relevant trials for secondary prevention include PROVE IT-TIMI 22 and the post-ACS statin data. JUPITER's contribution was specifically about primary prevention in the inflammatory-risk phenotype.

Frequently asked questions

›

References

Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207. PubMed
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934. PubMed
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease (CANTOS). N Engl J Med. 2017;377(12):1119-1131. PubMed
Cannon CP, Braunwald E, Murphy SA, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes (PROVE IT-TIMI 22). N Engl J Med. 2004;350(15):1495-1504. PubMed
Rosuvastatin prescribing information. U.S. Food and Drug Administration. FDA Label